US Melanoma Market Share And Trends Analysis By Type (Superficial Spreading, Nodular, Lentigo Maglina, Acral Lentigious And Others); Gender (Male And Female); Treatment (Immunotherapy, Biologic Therapy, Radiation Therapy, Chemotherapy, Surgery And Others); Diagnosis (Abcde, Ugly Duckling, Biopsy And Others), End Users (Hospitals, Pharmaceutical Companies, Research Centers, Clinics, Laboratories) - Forecast Till 2032

Table of Contents

1 Report Prologue

2 Market Introduction

2.1 Introduction

2.2 Scope of Study

2.3 Research Objective

2.4 Assumptions & Limitations

2.4.1 Assumptions

2.4.2 Limitations

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

4 Market Dynamics

4.1 Drivers

4.1.1 Increasing awareness regarding skin cancer

4.1.2 Increased emphasis on early detection of cancer

4.1.3 Increasing inclination towards preventive care

4.2 Restrains

4.2.1 Risk Associated with blood transfusion

5 Market Factor Analysis

5.1 Porter’s Five Forces Model

5.1.1 Bargaining power of suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Supply Chain Analysis

6 US Melanoma Market, By Type

6.1 Superficial melanoma

6.2 Nodular Melanoma

6.3 Lentigo Maglina Melanoma

6.4 Acral Lentigious

6.5 Others

7 US Melanoma Market, By Gender

7.1 Male

7.2 Female

8 US Melanoma Market, By Treatment

8.1 Immunotherapy

8.2 Biological therapy

8.3 Radiation

8.4 Chemotherapy

8.5 Surgery

8.6 Others

9 US Melanoma Market, By Diagnosis

9.1 ABCDE

9.2 Ugly Duckling

9.3 Biopsy

9.4 Others

10 US Melanoma Market, By End User

10.1 Hospitals

10.2 Pharmaceutical Companies

10.3 Research centres

10.4 Clinics

10.5 Laboratories

11 Competitive Landscape

11.1 Pricing of drugs for melanoma

11.2 Production Capacity of Major Players

12 Company Profile

12.1 Amgen Inc.

12.1.1 Overview

12.1.2 Product/Business Segment Overview

12.1.3 Financial Updates

12.1.4 Key Developments

12.2 Eristol-Mayers Squibb

12.2.1 Overview

12.2.2 Product/Business Segment Overview

12.2.3 Financial Updates

12.2.4 Key Developments

12.3 Eisai Co Ltd.

12.3.1 Overview

12.3.2 Product/Business Segment Overview

12.3.3 Financial Updates

12.4 F Hoffmann-La Roche Ltd

12.4.1 Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Updates

12.5 Genetech Inc.

12.5.1 Overview

12.5.2 Product/Business Segment Overview

12.5.3 Financial Updates

12.5.4 Key Developments

12.6 Janssen Biotech

12.6.1 Overview

12.6.2 Product/Business Segment Overview

12.6.3 Financial Updates

12.6.4 Key Developments

12.7 Pfizer

12.7.1 Company Overview

12.7.2 Product/Business Segment Overview

12.7.3 Financial Updates

12.7.4 Key Development

12.8 Novartis

12.8.1 Overview

12.8.2 Product/Business Segment Overview

12.8.3 Financial Overview

12.9 Vical

12.9.1 Overview

12.9.2 Product/Business Segment Overview

12.9.3 Financial Overview

12.10 Ziopharm

12.10.1 Overview

12.10.2 Product/Business Segment Overview

12.10.3 Financial Overview

13 Bibliography